医学
视网膜
眼科
临床试验
血管内皮生长因子受体
贝伐单抗
血管内皮生长因子
药理学
内科学
化疗
作者
Arshad M. Khanani,Matthew W. Russell,Aamir A Aziz,Carl J. Danzig,Christina Y. Weng,David A. Eichenbaum,Rishi P. Singh
摘要
The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.
科研通智能强力驱动
Strongly Powered by AbleSci AI